Cell Therapy Bioprocessing Market Size, Trends and Growth Analysis by 2027

The global market for cell therapy bioprocessing is projected to grow significantly, reaching approximately US$ 30,052.61 million by 2028, up from US$ 11,192.50 million in 2020. This growth represents a compound annual growth rate (CAGR) of 13.5% from 2021 to 2028.

Cell therapy bioprocessing is a specialized area within bioprocess engineering that connects the fields of cell therapy and biopharmaceutical manufacturing. As one of the most rapidly advancing sectors in life sciences, cell therapy involves the administration of live cells to patients for the treatment of chronic and rare diseases.

Despite being a niche within biotechnology, cell and gene therapy have attracted substantial investments from contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These companies are focusing on enhancing their manufacturing capabilities to provide cutting-edge therapies aimed at chronic illnesses. To expand their presence in the cell and gene therapy market, firms are employing both inorganic and organic growth strategies, including acquisitions and facility expansions.

Recent investments highlight the trend of companies entering the cell and gene therapy space. For example, in February 2020, Catalent, Inc. announced its intention to acquire MaSTherCell Global, Inc. for US$ 135 million. This acquisition is expected to leverage MaSTherCell's research and development resources, allowing Catalent to establish its own development and commercial manufacturing capabilities.

In another instance, Rentschler Biopharma, a CDMO based in Germany, expanded its manufacturing capabilities at the Cell and Gene Therapy (CGT) Catapult in the UK in February 2021. This move aims to facilitate entry into the regenerative medicine sector and initiate the production of adeno-associated virus (AAV) vectors for cell and gene therapies. Rentschler Biopharma plans to invest an undisclosed amount over the next five years while sharing its expertise with CGT Catapult.

Such investments are anticipated to invigorate the sector and propel advancements in cell therapy bioprocessing in the near future. Furthermore, biopharmaceutical companies have significantly increased their investments in cell and gene therapy in recent years. According to the Alliance for Regenerative Medicine (ARM), investments in this area doubled in 2020 compared to 2019, and were substantially higher than in 2018. In 2020, global investments reached US$ 19.9 billion, compared to US$ 13.5 billion in 2018 and US$ 9.8 billion in 2019. This influx of capital is expected to foster a thriving market in the coming years.

The cell therapy bioprocessing market is categorized by technology into several segments, including bioreactors, lyophilization, electrospinning, control flow centrifugation, ultrasonic lysis, genome editing technology, cell immortalization technology, and viral vector technology. In 2020, the bioreactor segment dominated the market, while the genome editing technology segment is projected to experience the highest CAGR of 14.5% during the forecast period.

When segmented by cell type, the market includes stem cells, immune cells, human embryonic stem cells, pluripotent stem cells, and hematopoietic stem cells. The stem cell segment held the largest market share in 2020 and is expected to achieve the highest CAGR of 14.0% in the forecast period.

In terms of indications, the market is divided into cardiovascular diseases (CVD), oncology, wound healing, orthopedic applications, and others. The oncology segment was the largest in 2020, while the orthopedic segment is anticipated to grow at the highest CAGR of 14.3% during the forecast period.

Key secondary sources utilized in the preparation of the report on the cell therapy bioprocessing market include the Central Drugs Standard Control Organization, the Commission for Protection against Health Risks, various Contract Research Organizations, and the Drug Safety and Effectiveness Network.